Cannabis
Debunking Myths: The Truth About Medical Cannabis and Its Impact on Brain Health
A study using fMRI to assess the impact of medical cannabis on brain activity over a year found no significant changes in areas related to working memory, reward processing, or impulse control. This challenges concerns about long-term cognitive effects. However, researchers note the need for larger, diverse samples to confirm these findings.
Medical cannabis is increasingly being used as an alternative form of therapy for people suffering from various ailments, such as chronic pain, anxiety, depression, and sleep problems. Despite its growing popularity, there are many myths and concerns surrounding its use, especially regarding its potential negative effects on brain function. The public often believes that cannabis use leads to memory impairment, impulse control disorders, and a negative impact on the ability to process rewards.
A new study by the American Medical Association, however, has some surprising and reassuring conclusions. The results, published in the prestigious journal JAMA Network Open, suggest that a year of medical cannabis use has no significant effect on key cognitive processes such as working memory, inhibitory control, and reward processing. These findings could be groundbreaking for medical marijuana patients, allaying concerns about the long-term effects of its use.
Description of the study
The study was designed to specifically assess whether medical cannabis use affects brain activity during cognitive tasks. Researchers recruited 57 participants from the Boston area who obtained medical cannabis cards to treat symptoms such as anxiety, depression, pain, and insomnia. Participants were then examined in detail using functional magnetic resonance imaging (fMRI), which monitored brain activity during a variety of cognitive tasks.
The study included two key time points: before marijuana use began and after a year of regular use. This method allowed for the assessment of changes in brain activity and the examination of whether long-term cannabis use affected areas responsible for working memory, reward processing, and impulsive control
Research results
Analysis of fMRI results showed that there were no significant differences in brain activity between the initial state and after one year of medical cannabis use. This means that cannabis use did not significantly affect the functioning of the studied brain areas, which contradicts common concerns about the harmfulness of long-term cannabis use on cognitive functions.
Working memory (N-back task): Participants were given a test of working memory, which assesses the ability to store and manipulate information in a short period of time. The study found no changes in brain activation in the areas responsible for this function, suggesting that cannabis does not negatively affect short-term memory.
Reward Processing (Monetary Incentive Delay task): The next test was a task that assessed the ability to process rewards and respond to motivational stimuli. The results showed that brain activation in areas associated with reward processing, such as the nucleus accumbens, remained unchanged.
Inhibitory control (Stop Signal task): The last task assessed inhibitory control, or the ability to stop and control impulsive reactions. Again, no significant changes in brain activation were observed after a year of cannabis use.
Conclusions from the study
The study suggests that using medical cannabis for therapeutic purposes, such as treating pain, anxiety, depression, or insomnia, does not cause significant changes in brain activity in key cognitive areas. This finding is especially important for patients who worry about the negative effects of cannabis on their mental abilities.
The researchers emphasize that while the results are promising, further research is needed with larger and more diverse samples to more precisely examine the effects of cannabis on different groups of users, including younger people and those using higher doses.
These findings could change the way medical cannabis is viewed and allay concerns among patients and physicians about its long-term effects on cognitive function. Further research could lead to a better understanding of marijuana’s effects on the brain and help optimize its therapeutic properties.
Context of the results in relation to previous studies
The findings of the latest American Medical Association study contrast with previous research that has repeatedly shown negative effects of marijuana use, especially among young users and heavy recreational users. Many previous studies have suggested that long-term cannabis use can lead to declines in cognitive function, including working memory, attention, and impulse control.
One of the main problems with previous studies has been their methodology—most were cross-sectional studies, meaning they compared groups of cannabis users with people who never used it, without being able to track long-term changes in the same people. As a result, it was difficult to determine whether the differences observed were a result of cannabis use or if they existed beforehand.
A study conducted by the American Medical Association aimed to address these limitations by using a longitudinal approach, where changes in brain activity were monitored before and after a year of medical cannabis use. Furthermore, these studies focused on medical users, not recreational users, allowing for more precise inferences about the effects of marijuana for therapeutic purposes.
What the Results Mean for Medical Marijuana Patients
For many medical cannabis patients, the results of this study could be incredibly reassuring. Concerns about the potential negative effects of cannabis on cognitive function have often led to hesitance to use it, despite health benefits such as pain relief, improved sleep, and reduced anxiety symptoms. The results of this study suggest that patients can benefit from medical cannabis therapy without fear of long-term changes in key brain regions.
Other studies support these findings, indicating that medical cannabis use, especially in moderate doses, has minimal impact on cognitive function. For example, studies of cancer patients found that medical cannabis not only helped with pain management but also improved mental clarity, a significant contrast to the stereotypes associated with its recreational use.
Limitations of the study
Although the study results are promising, they should be interpreted in the context of several limitations. First, the sample of participants was relatively homogeneous—most were older, well-educated, and predominantly white, which may limit the generalizability of the results to the entire medical cannabis population. The lack of ethnic and age diversity in the study sample suggests the need for future research with more diverse groups.
Additionally, part of the study took place during the COVID-19 pandemic, which may have affected the sample size and final results. Some participants dropped out of the study due to fear of infection, which may have reduced the statistical power of the results and introduced additional variables that were not fully controlled.
Final conclusions
A study conducted by the American Medical Association has important and reassuring conclusions for medical cannabis users. The results suggest that a year of therapeutic cannabis use does not cause significant changes in key brain regions responsible for working memory, impulse control, and reward processing. This finding is especially important in the context of concerns among patients and physicians who often hesitate to recommend cannabis therapy due to potential side effects.
However, to fully understand the long-term effects of medical cannabis on the brain, further research is needed in larger, more diverse populations, with different doses, forms of consumption, and specific patient groups. Further research will help not only to better understand the health effects of cannabis, but also to optimally tailor therapy to the needs of individual patients, maximizing health benefits and minimizing potential risks.
__
(Featured image by R+R Medicinals via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in FaktyKonopne. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us
-
Markets2 weeks ago
Fed’s Bold 50 bp Cut: Do They Know Something We Don’t?
-
Fintech3 days ago
Qonto Launches in Austria and Three Other European Markets
-
Crypto1 week ago
Celestia (TIA) Raised $100 Million in Venture Capital
-
Crypto1 day ago
Ethereum: In 2025, ETH Staking Bonuses Could Beat the US Base Interest Rate